NCT00710801已完成不适用
Randomized, Open-label Study to Evaluate the Hepatitis C Virus (HCV) Burden in Patients Receiving Cyclosporine (Neoral or CSA) Versus Tacrolimus (Prograf) in de Novo Liver Recipients Receiving Mycophenolate Sodium (Myfortic): Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to learn about how different immunosuppressant therapies impact on recurrent hepatitis C virus infection in the new liver after liver transplant. We will be evaluating if Cyclosporin A has a superior effect against recurrent Hepatitis C virus (HCV) infection than Tacrolimus.
详细描述
We will address the hypothesis that CSA has a superior antiviral effect against HCV than Tacrolimus by assessing serial HCV RNA levels in serum. We plan to address the hypothesis that CSA is more efficient in limiting viremia than Tacrolimus and that viremia is predictive of long-term clinical outcome of hepatic fibrosis that is known to impact on both graft and patient survival
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •About to undergo a primary liver transplant (including living donor, split liver) and are HCV positive.
- •Willing and capable of giving written consent for study participation
- •Expected to be capable of study participation for full 24 months post-transplantation.
- •Allograft biopsies will be possible
- •Expected use of calcineurin inhibitor (Neoral or Tacrolimus) as primary immunosuppression An immunosuppressive regimen consisting of a calcineurin inhibitor (Neoral or Tacrolimus) in combination with Simulect and MYCOPHENOLATE SODIUM
排除标准
- •This is a multi-organ transplant or if the patient has previously been transplanted with any other organ.
- •This is a liver transplant from a non-heart beating donor.
- •This is an ABO incompatible transplant.
- •Patients with serum creatinine level > 250 umol/L.
- •The recipient is seropositive for human immunodeficiency virus (HIV) antibodies.
- •Fulminant liver failure is the reason for transplant.
- •Patient is participating in other clinical trial involving exploratory drug
- •There is a known malignancy, or a history of malignancy, other than successfully treated non-metastatic basal or squamous cell carcinoma of the skin, or hepatocellular carcinoma less than 5 cm meeting Milan criteria for transplantation
- •The patient is being transplanted for hepatic malignancy with greater than 5 known lesions.
- •Severe coexisting disease is present or if any unstable medical condition is present which could affect the study objectives.
- •A female transplant candidate is pregnant, lactating or of childbearing potential and not practicing an acceptable method of contraception.
- •An unlicensed drug or therapy has been administered within one month prior to study entry or if such therapy is to be instituted post-transplantation.
研究者
研究点 (1)
Loading locations...
相似试验
终止
不适用
Polycystic Liver Disease in Kidney TransplantPolycystic Liver DiseaseNCT00934791Mayo Clinic2
已完成
3 期
Tacrolimus Versus Cyclosporine for Immunosuppression After Lung TransplantationBronchiolitis ObliteransImmunosuppressionNCT01429844Universitätsklinikum Hamburg-Eppendorf274
Unknown
3 期
Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAAAcquired Aplastic Anemia.NCT01844635Nagoya University320
撤回
4 期
Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for HypophosphatasiaHypophosphatasiaNCT06015750Alexion Pharmaceuticals, Inc.8
已完成
4 期
Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid ArthritisRheumatoid ArthritisNCT02557100Bristol-Myers Squibb80